Deep Dive Day Workshops

Monday August 30, 2021
8.00am-5.00pm EDT | 5.00am-2.00pm PDT

Workshop A

9.00 / 6.00 Investigating Solid Tumor Biology to Inform Therapeutic Design

Download The Event Guide To See Full Sessions Details

Siler Panowski, Director Solid Tumor Biology, Allogene Therapeutics
David Martin, Chairman & CSO, Xyphos: An Astellas Company

Workshop B

9.00 / 6.00 Investigating the Mechanisms of Resistance & Strategies to Equip T-Cells to Overcome Antigen Escape

Download The Event Guide To See Full Sessions Details

Beau Webber, Assistant Professor, Department of Pediatrics, University of Minnesota
Renier Brentjens, Director Cellular Therapeutics, Memorial Sloan Kettering Cancer Center
Joaquín Arribas, Director of Preclinical Research, Vall D’Hebron Institute of Oncology

Workshop C

9.00 / 6.00 Realizing an ‘Off-the-Shelf’ Future for Cell Therapies

Download The Event Guide To See Full Sessions Details

Kurt Gunter, CMO, Kuur Therapeutics

Stewart Abbot, CSO & COO, Adicet Bio

Gary Lee, CSO, Senti Biosciences

Workshop D

9.00 / 6.00 Scaling Out Autologous & Scaling Up Allogeneic Cell Therapy Processes for Affordable, Accessible Products

Download The Event Guide To See Full Sessions Details

Gregory Russotti, CTO, Century Therapeutics

Hari Kamaraju, Head of Manufacturing Excellence, Advanced Therapies, Johnson & Johnson

Dan Bright, Director Manufacturing Operations, Cellectis

11.00am / 8.00am Break

Post-Lunch Workshops:

Workshop E

11.30 / 8.30 Developing Platforms for Target Identification & Safety Validation for Solid Tumors

Download The Event Guide To See Full Sessions Details

Reagan Jarvis, CEO, Anocca
Roman Yelensky, CTO, Gritstone Oncology
Grace Zheng, Director of Computational Biology & Machine Learning, ArsenalBio

Workshop F

11.30 / 8.30 Pharmacometrics and Systems Pharmacology Approaches to Inform Clinical Outcomes of Cell Therapies

Download The Event Guide To See Full Sessions Details

Aman Singh, Associate Director Clinical Pharmacology M&S, Cell Therapies, Takeda
Weirong Wang, Scientific Director, Johnson & Johnson

Workshop G

11.30 /8.30 Understanding and Managing Toxicity to Enhance Patient Outcomes

Download The Event Guide To See Full Sessions Details

Adrian Bot, Global Head Global Head Translational Medicine, Kite: A Gilead Company
Michele Hooper, VP Safety & Pharmacovigilance, Kite: A Gilead Company

Workshop H

11.30 / 8.30 Designing Practical Facilities for Interconnected Departments & Sites

Download The Event Guide To See Full Sessions Details

IPS

1.30pm / 10.30am Break

Afternoon Workshops:

Workshop I

2.00pm / 11.00am Examining TILs as a Natural Multi-Targeting Therapy Against Solid Tumors

Download The Event Guide To See Full Sessions Details

Beau Webber, Assistant Professor, Department of Pediatrics, University of Minnesota

Workshop J

2.00pm / 11.00am Identifying Desirable Characteristics & Cell Populations to Achieve Quality Over Quantity

Download The Event Guide To See Full Sessions Details

Alex Karlsson-Parra, CSO, Immunicum

Workshop K

2.00pm / 11.00am Optimizing Clinical Management of Apheresis & Cryopreservation

Download The Event Guide To See Full Sessions Details

Dirk De Naeyer, COO, Kiadis Pharma

Workshop L

2.00pm / 11.00am Unlocking the Full Potential of Outcomes Based Contracting Work for CGT: Collaborate or Compete?

Download The Event Guide To See Full Sessions Details

Santanu Das, Managing Director, Life Sciences Practice, Huron Consulting Group
Sarabvijay Singh, Senior Director, Huron Consulting Group
Maya Khurana, Director - Market Access & Commercial Strategy, Huron Consulting Group
Filiz Yucebay, Manager, Pharmacy Consultant, Huron Consulting Group

4.00pm / 1.00pm Networking

Diversity in CAR-TCR

4.30pm -6.30pm / 1.00pm -3.00pm

Prioritizing Diversity, Equity & Inclusion in the Cell and Gene Field

Delfi Krishna, Head of Strategic Operations, Immatics
Jane Grogan, Former Head of Adaptive Cell Therapy and IO, Genentech
Shon Green, Senior Director, Translational Sciences, Umoja Biopharma
Tam Soden, Executive Director & Global Head of Quality, Kite: A Gilead Company

diversity